PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400994
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400994
Dendritic Cell Cancer Vaccine market size was valued at USD 539.42 Million in 2022, expanding at a CAGR of 12.22% from 2023 to 2030.
A dendritic cell cancer vaccine is a treatment method in which dendritic cells, a kind of immune cell, are used to activate the patient's immune system to target and eliminate cancer cells. Dendritic cells are loaded with cancer-specific antigens from either the patient's own tumor or synthetic sources before being reintroduced into the patient's body. This process stimulates the immune system, making it more capable of recognizing and attacking cancer cells. Dendritic cell cancer vaccines are being researched as a possible immunotherapy to treat many forms of cancer and boost the body's natural defenses against the illness.
Dendritic Cell Cancer Vaccine Market Dynamics
The rise in the number of cancer patients to propel the market growth
Increased government support for the development of cancer vaccines, as well as breakthroughs in vaccination technology, are driving market expansion. Male cancer cases were anticipated to reach 15,585,096 by 2040, while female cancer cases were expected to reach 13,302,846 by 2040. The growing prevalence of cancer among the worldwide population is likely to fuel market expansion. Similarly, the European Cancer Information System reported in 2020 that the projected incidence of non-melanoma skin cancers in 2020 was 2,681,958 and was predicted to rise to 3,244,076 by 2040. The rising prevalence of cancer in various nations is likely to fuel demand for cancer vaccines, propelling market expansion over the next several years.
Dendritic Cell Cancer Vaccine Market- Key Insights
As per the analysis shared by our research analyst, the Global Dendritic Cell Cancer Vaccine market is estimated to grow annually at a CAGR of around 12.22% over the forecast period (2023-2030)
The Dendritic Cell Cancer Vaccine market is projected to grow at a significant rate due to the rise in the number of cancer patients to propel the market growth
Based on Type segmentation, Sipuleucel-T (Provenge) was predicted to show maximum market share in the year 2022
Based on End-User segmentation, Adults were the leading End-User in 2022
On the basis of region, North America was the leading revenue generator in 2022
The Global Dendritic Cell Cancer Vaccine market is segmented on the basis of Type, End-User, and Region.
The market is divided into categories based on Type: By creaVax, sipuleucel-T (Provenge), and others. Sipuleucel-T's potential to successfully boost an individual's immunity against tumor cells is increasing its market demand. The vaccine was licensed by the US Food and Drug Administration in 2010 for the treatment of castrate-resistant prostate cancer. Many studies have found that utilizing Sipuleucel-T increases immunity, has few negative effects, and increases a survivor's longevity.
The market is divided into categories based on End-User: Pediatrics and Adults. Due to the increasing number of cancer cases throughout the world in 2022, the adult vaccinations market category had the largest market share. Additionally, a large number of researchers throughout the world are doing in-depth studies to generate efficient vaccination candidates to realize prospective treatment solutions.
Dendritic Cell Cancer Vaccine Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America region is expected to grow. In 2022, the market for dendritic cell cancer vaccines will be dominated by North America. An extraordinary increase in cancer cases and numerous research studies supported by university research institutes and pharmaceutical behemoths are mostly to blame for the region's dendritic cell cancer vaccine market expansion.
Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, technology, reputation, and availability. Some of the primary Types used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions.
In February 2022, Medigene and BioNTech have agreed to work together to develop T-cell immunotherapies that target several solid tumor sites. Through the partnership, Medigene's preclinical T-cell receptors (TCR) initiatives, which employ Medigene's switch-receptor technology for the creation of TCR treatments and dendritic cell vaccines, will be acquired by BioNTech.
The scope of this report covers the market by its major segments, which include as follows: